Novartis Ag (NVS) Operating Leases (2019 - 2026)
Novartis Ag (NVS) posted Operating Leases of $1.7 billion for Q2 2026, little changed sequentially from $1.7 billion in Q4 2025, and up 4.33% YoY from $1.6 billion in Q2 2025.
Novartis Ag (NVS) Operating Leases (2019 - 2026) Analysis & Trends
Novartis Ag has reported Operating Leases for 8 years, with the latest figure at $1.7 billion in Q2 2026.
- Quarterly Operating Leases rose 4.33% year-over-year to $1.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 4.33% YoY) and the FY2025 annual result came in at $1.7 billion, up 3625.53% from the prior year.
- Operating Leases held at $1.7 billion in Q2 2026 per NVS's latest filing, from $1.7 billion in the prior quarter.
- Over five years, Operating Leases peaked at $1.7 billion in Q2 2026 and troughed at -$47.0 million in Q4 2024.
- A 5-year average of $671.7 million and a median of $84.5 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases jumped 12975.0% in 2023, then slumped 132.19% in 2024.
- Over 5 years, Operating Leases stood at $23.0 million in 2022, then soared by 534.78% to $146.0 million in 2023, then plunged by 132.19% to -$47.0 million in 2024, then soared by 3625.53% to $1.7 billion in 2025, then rose by 0.36% to $1.7 billion in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $1.7 billion, $1.7 billion, and $1.6 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Bn |
| Dec 31, 2025 | 1.66 Bn |
| Jun 30, 2025 | 1.59 Bn |
| Dec 31, 2024 | -47.00 Mn |
| Sep 30, 2024 | -45.00 Mn |
| Jun 30, 2024 | 1.56 Bn |
| Dec 31, 2023 | 146.00 Mn |
| Jun 30, 2023 | 1.55 Bn |
| Dec 31, 2022 | 23.00 Mn |
| Sep 30, 2022 | -12.00 Mn |
| Jun 30, 2022 | -12.00 Mn |
| Mar 31, 2022 | -12.00 Mn |
| Dec 31, 2021 | 1.90 Bn |
| Jun 30, 2021 | 1.66 Bn |
| Dec 31, 2020 | -44.00 Mn |
| Sep 30, 2020 | -44.00 Mn |
| Jun 30, 2020 | -44.00 Mn |
| Mar 31, 2020 | -44.00 Mn |
| Dec 31, 2019 | 96.00 Mn |
| Jun 30, 2019 | 2.05 Bn |